Cargando…
BMI1: A Biomarker of Hematologic Malignancies
BMI1 oncogene is a catalytic member of epigenetic repressor polycomb group proteins. It plays a critical role in the regulation of gene expression pattern and consequently several cellular processes during development, including cell cycle progression, senescence, aging, apoptosis, angiogenesis, and...
Autor principal: | Sahasrabuddhe, Anagh A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859448/ https://www.ncbi.nlm.nih.gov/pubmed/27168727 http://dx.doi.org/10.4137/BIC.S33376 |
Ejemplares similares
-
Deletion analysis of BMI1 oncoprotein identifies its negative regulatory domain
por: Yadav, Ajay K, et al.
Publicado: (2010) -
SIGNALING PATHWAYS AS BIOMARKERS
por: Sahasrabuddhe, Anagh A., et al.
Publicado: (2016) -
CD markers polymorphisms as prognostic biomarkers in hematological malignancies
por: Shahrabi, Saeid, et al.
Publicado: (2020) -
Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools
por: Khalife, Jihane, et al.
Publicado: (2020) -
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
por: Testa, Ugo, et al.
Publicado: (2014)